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Abstract
 
Cyclooxygenases (Cox) are rate-limiting enzymes that initiate the conversion of arachidonic
acid to prostanoids. Cox-2 is the inducible isoform that is upregulated by proinflammatory
agents, initiating many prostanoid-mediated pathological aspects of inflammation. In this study,
we demonstrate that interferon (IFN)-
 
g
 
 alone or in synergy with lipopolysaccharide (LPS) or
interleukin 1
 
a 
 
induces Cox-2 expression in mouse peritoneal macrophages, which is paralleled
by changes in Cox-2 protein levels and prostaglandin E
 
2
 
 (PGE
 
2
 
)
 
 
 
release. Induction of Cox-2
was abrogated in macrophages that lack IFN regulatory factor (IRF)-1, consistent with an at-
tenuated
 
 
 
hepatic mRNA response in IRF-1
 
2
 
/
 
2
 
 mice injected with LPS. Conversely, the ab-
sence of IRF-2 in macrophages resulted in a significant increase in both basal and inducible
 
Cox-2 gene and protein expression as well as IFN-
 
g
 
–stimulated PGE
 
2 
 
release, identifying IRF-2
 
as negative regulator of this promoter. Two IFN stimulation response elements were identi-
fied in the mouse Cox-2 promoter that were highly conserved in the human Cox-2 gene.
Both bind endogenous IRF-1 and IRF-2 and regulate transcription in an IRF-1/2–dependent
manner. Our data demonstrate conclusively the importance of IFN-
 
g
 
 as a direct activator and
coactivator of the Cox-2 gene, and the central role of IRF-1/2 family members in this process.
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Introduction
 
PGs are involved in homeostatic, developmental, and in-
flammatory processes (1). PG endoperoxidase H synthases
(PGHSs),
 
1
 
 also called cyclooxygenases (Cox), are the rate-
limiting enzymes that initiate conversion of arachidonic
acid to all PGs, prostacyclins, and thromboxanes (2). Two
distinct Cox genes have been cloned and characterized.
They encode similar proteins, sharing 60% amino acid se-
quence identity, although they are expressed after different
developmental and temporal patterns (3). Cox-1, also
known as the “constitutive” cyclooxygenase, is detected in
almost all tissues. This enzyme is believed to be responsible
for the production of PGs involved in the maintenance of
homeostasis. Cox-2, the “inducible” cyclooxygenase, is not
generally expressed basally, but is rapidly and strongly acti-
vated in many cells upon induction with a variety of proin-
flammatory agents, cytokines, hormones, and tumor pro-
moters (2).
IFN-
 
g
 
 is considered to be a potent regulator of immu-
nological and inflammatory responses (4). A homodimer of
IFN-
 
g
 
 initially binds to the 
 
a
 
 chain of a heterodimeric re-
ceptor that carries Janus kinase (JAK)1. Dimerization with
IFN-
 
g
 
 receptor 
 
b
 
 chains that carry JAK2, transphosphory-
lation of JAK kinases, and ultimately phosphorylation of
preformed cytosolic signal transducer and activator of
transcription (STAT)1
 
a
 
 subunits, follow. Phosphorylated
STAT1
 
a
 
 homodimers translocate to the nucleus and acti-
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g
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vate several primary IFN-
 
g
 
 response genes by binding to
IFN-
 
g
 
–activated sites within their promoters. Among these
IFN-
 
g
 
 primary response genes are several IFN regulatory
factors (IRFs [5, 6]), a growing family of transcription fac-
tors that contains, among others, IRF-1 and IRF-2. IRF-1
is strongly inducible by IFN-
 
g
 
 and binds IFN-stimulated
responsive elements (ISREs) within promoters, activating
transcription. In contrast, IRF-2 is constitutively expressed
and acts mostly as a repressor by competing with IRF-1 for
the same cis-element (the ISRE has also been called IRF-
1/IRF-2 binding sequence motif, or IRF-E), and possibly
by repressing activators positioned nearby in the promoter
(6–8). These ISREs, usually defined by palindromic TTTC
sequences separated by two or three nucleotides (9, 10), are
located in the promoter region of many IFN-inducible
genes. It has been shown that IRF-1–deficient cells exhibit
impaired induction of several genes involved in the innate
immune response, including the 2-5A synthetase (11), in-
ducible nitric oxide synthase (iNOS [12]), and IL-12 p40
and p35 genes (13). Similarly, dysregulated nitric oxide
(NO) release (14) and IL-12 gene induction (13) and secre-
tion have been reported for IRF-2–deficient macrophages.
In this report, we show that IFN-
 
g
 
 works as a pivotal
regulator of the Cox-2 gene, activating its expression or
coactivating LPS- and IL-1
 
a
 
–dependent Cox-2 expression
in primary murine macrophages. This regulation is depen-
dent on the expression of IRF-1, and requires the presence
of two novel ISREs that are localized in the promoter of
the murine Cox-2 gene and are conserved in the human
Cox-2 gene. Importantly, our data reveal a mechanism for
negative regulation of the Cox-2 gene through IRF-2 ac-
tion.
 
Materials and Methods
 
Reagents and Antibodies. 
 
Purified recombinant murine IFN-
 
g
 
(1.3 
 
3
 
 10
 
7
 
 U/
 
m
 
g) was provided by Genentech, Inc. Protein-free
(
 
,
 
0.008%, phenol/water-extracted) 
 
Escherichia coli
 
 K235 LPS was
prepared by the method of McIntire et al. (15). Mouse rIL-1
 
a
 
was provided by Hoffmann-LaRoche. Anti–Cox-1 (no. 160110)
and anti–Cox-2 (no. 160116) antibodies were purchased from
Cayman Chemical. Rabbit polyclonal antibodies to IRF-1, IRF-2,
and IFN consensus sequence binding protein (ICSBP) were as
described previously (16, 17).
 
Mice. 
 
All animals were housed in cages with filter tops in a
laminar-flow hood, fed food and acid water ad libitum, and bred
in a virus antibody–free facility. Mice with a targeted mutation in
the IRF-1 or IRF-2 gene (homozygous [
 
2
 
/
 
2
 
] mice and their
heterozygous [
 
1
 
/
 
2
 
] littermates) were originally obtained from
Dr. Tak Mak (Amgen Institute, Toronto, Canada) and had been
backcrossed to C57BL/6 mice three to five times. The IRF-1
 
2
 
/
 
2
 
and IRF-2
 
2
 
/
 
2
 
 colonies have been maintained at Uniformed Ser-
vices University of the Health Sciences as detailed elsewhere (14).
Whenever possible, IRF-1
 
1
 
/
 
1
 
 and IRF-2
 
1
 
/
 
1
 
 mice derived from
heterozygous littermates were used as controls; otherwise,
C57BL/6J
 
1
 
/
 
1
 
 mice (The Jackson Laboratory) were used. All
mice bred for use in this study were genotyped. Male and female
mice were used and were typically between 6 and 12 wk of age.
For temporal analysis of Cox-2 expression in the liver, mice were
injected intraperitoneally with 25 
 
m
 
g (
 
z
 
1–1.4 mg/kg) of LPS. In
 
these experiments, groups of four mice were used for each time
point. Experiments were carried out according to the institu-
tional ethical guidelines for animal experiments and safety guide-
lines for gene manipulation experiments.
 
Tissue Culture.
 
Peritoneal macrophages from all mice were
isolated 4 d after intraperitoneal injection of 3 ml of sterile 3%
thioglycollate broth. Cells were washed with pyrogen-free saline
and resuspended in RPMI 1640 supplemented with 2 mM
 
l
 
-glutamine, 100 IU/ ml of penicillin, 100 
 
m
 
g/ml streptomycin, 10
mM Hepes, 0.3% sodium bicarbonate, and 2% FCS, then were
plated in six-well plates (4 
 
3
 
 10
 
6
 
 cells/well) and incubated over-
night at 37
 
8
 
C and 6% CO
 
2
 
. Cells were washed twice with PBS to
remove nonadherent cells, and were incubated with different
stimuli or vehicle for the indicated time periods. The RAW
264.7 macrophage cell line was obtained from the American
Type Culture Collection and was cultured in RPMI medium
supplemented with 10 mM Hepes, 0.3% sodium bicarbonate, 2
mM 
 
l
 
-glutamine, 100 IU/ml of penicillin, 100 
 
m
 
g/ml of strepto-
mycin, and 10% FCS, and was incubated as described above.
 
Analysis of mRNA. 
 
Total RNA from cultured macrophages
or from the livers of individual LPS-treated mice was isolated us-
ing RNA-Stat60 (Tel-Test) according to the manufacturer’s in-
structions. The relative quantities of mRNA for Cox-1, Cox-2,
and the “housekeeping gene,” hypoxanthine guanine phospho-
ribosyl transferase (HPRT), were determined by coupled reverse
transcription (RT)-PCR. The primers and probes used in each
case were as follows: Cox-1 sense primer 5
 
9
 
-CCCAGAGTCAT-
GAGTCGAAGGAG-3
 
9
 
, antisense 5
 
9
 
-CAGGCGCATGAGTAC-
TTCTCGG-3
 
9
 
, and probe CCAGTGTGATTGTACTCGCACG;
Cox-2 (18) sense primer 5
 
9
 
-GCAAATCCTTGCTGTTCCA-
ATC-3
 
9
 
, antisense primer 5
 
9
 
-GGAGAAGGCTTCCCAGCTT-
TTG-3
 
9
 
, and probe CCCACTTCAAGGGAGTCTGGAACA;
HPRT (19) sense primer 5
 
9
 
-GTTGGATACAGGCCAGAC-
TTTGTTG-3
 
9
 
, antisense primer 5
 
9
 
-GATTCAACTTGCGCT-
CATCTTAGGC-3
 
9
 
, and probe GTTGTTGGATATGCCCT-
TGAC. Enhanced chemiluminescence reagents (Amersham
Pharmacia Biotech) were used for visualization of the amplified
RNA transcripts after electrophoresis of the samples and Southern
blot hybridization.
 
Plasmid Construction and Transfection. 
 
PGHS-2 “short” and
“long” reporters were as described previously (20). PGHS-2 “me-
dium” was constructed by cloning the 2.1-kb BglII-Hind III frag-
ment from PGHS-2 long into the same sites in pGL2 basic lu-
ciferase vector. The PGHS-2 (
 
2
 
43) reporter, which contains the
basic promoter, initiator sequence, and 88 bp of untranslated
region from the murine Cox-2 gene, was constructed by PCR
amplification of PGHS-2 long plasmid with GL2 (Promega) and
5
 
9
 
-GCGCGCGCCTCGAGCCGCTTACAGACTTAAAAGCA-
AGGTTC-3
 
9
 
 primers, and the resulting fragment was inserted
into pGL2 basic vector. ISRE I (
 
2
 
43) and ISRE II (
 
2
 
43) were
constructed by cloning three copies of the ISRE I (5
 
9
 
-TAAAA-
CAGAAAACAAGAAC-3
 
9
 
) and ISRE II (5
 
9
 
-CCTTTCATTT-
TTGTTTTGTT-3
 
9
 
) sequence into the SmaI-SacI site of PGHS-2
(
 
2
 
43) plasmid. Mutant versions of these ISREs (ISRE I mutant:
5
 
9
 
-TAAAACATTAAACAATTAC-3
 
9
 
, ISRE II mutant: 5
 
9
 
-CCT-
AACATTTTAATTTTGTT-3
 
9
 
) were cloned as described above.
Guanylate binding protein (GBP)-Ld40 and AP1-Ld40 luciferase
reporters were described previously (21, 22). All reporter con-
structs were confirmed by sequencing analysis. The IRF-1 expres-
sion vector was constructed by cloning its cDNA into the EcoRI
site in pcDNA3.1 vector (Invitrogen). IRF-2 expression vector
was described previously (22, 23). For transfection, RAW 264.7
cells were seeded the night before the experiment on 24-well 
2133
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plates (2 
 
3
 
 10
 
5
 
 cells per well). The next day, reporter plasmid (0.2
 
m
 
g) and expression vectors for IRF-1, IRF-2, or control plasmids
were transfected along with 0.25 
 
m
 
g of pBluescript II SK(
 
1
 
) and
0.125 
 
m
 
g of 
 
b
 
-galactosidase expression plasmid (pCH110; Amer-
sham Pharmacia Biotech) using SuperFect transfection reagent
(Qiagen) as described (23). After transfection (3 h), cells were in-
cubated with fresh media, IFN-
 
g
 
 (10 U/ml), and/or LPS (1 ng/
ml) for an additional 24 h. Luciferase and 
 
b
 
-galactosidase activity
were measured as described previously (22), and 
 
b
 
-galactosidase
activity was used for normalization of the luciferase activity within
each treatment.
 
Western Blot Analysis.
 
Whole cell extracts were prepared
from peritoneal macrophages after treatment with different stim-
uli using a lysis buffer containing 20 mM Tris-HCl, pH 7.9, 100
mM NaCl, 1% NP-40, 1 mM dithiothreitol (DTT), 0.5 mM
phenylmethylsulfonyl fluoride, and a cocktail of protease inhibi-
tors (Complete™; Boehringer). Crude extracts were passed
through a 23-gauge needle 10 times to disrupt cells completely,
and were centrifuged to remove debris. Supernatants were sub-
jected to 10% SDS-PAGE, transferred to Immobilon-P mem-
branes (Millipore), and probed with the indicated antibodies.
Horseradish peroxidase–conjugated anti–rabbit or anti–mouse an-
tibodies and reagents for enhanced chemiluminescence detection
were obtained from Amersham Pharmacia Biotech.
 
Bead Assay for Detection of DNA-binding Proteins. 
 
For DNA
capture using magnetic beads, nuclear extracts from IFN-
 
g
 
–
treated RAW 264.7 cells were obtained using the method of
Dignam et al. (24), with modifications. Cells were washed with
PBS and incubated for 15 min in buffer A (10 mM Hepes, pH
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, and protease
inhibitors) at 4
 
8
 
C. Cells were pelleted and resuspended in fresh
buffer A and homogenized using a Dounce homogenizer for 10
strokes. The nuclear pellet was finally resuspended in buffer C (20
mM Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA, and protease inhibitors) and incubated for 15 min at 4
 
8
 
C,
with rotation. Nuclear debris was pelleted, and supernatants were
snap-frozen at 
 
2
 
708C. Biotinylated DNA fragments containing dif-
ferent regions of the Cox-2 promoter were prepared by PCR re-
actions using the different luciferase reporter constructs and GL2
and biotinylated GL1 primers. Approximately 30 pmol of each
fragment was immobilized onto magnetic beads (Dynabeads
M280 streptavidin; Dynal) according to the manufacturer’s pro-
cedure. In all cases, 95% of the biotinylated DNAs were attached
to the beads. For capturing DNA binding proteins, 500 mg of nu-
clear proteins was incubated with 200 mg of DNA-conjugated
beads for 2 h at 48C. Beads were washed three times using buffer
C, and were resupended in SDS-loading buffer and subjected to
SDS-PAGE and Western blot analysis.
Electrophoretic Mobility Shift Assay. Primers for Cox-2 ISRE I
(59-TTCCCGCATTTAAAATAAAACAGAAAACAAGAACT-
ATTTAAA-39 and complementary strand) and Cox-2 ISRE II
(59-TGTGGATATTCTCCCCTTTCATTTTTGTTTTGTTT-
TGTTCT 39 and complementary strand) were annealed and 32P-
endlabeled with T4 polynucleotide kinase (Promega). Nuclear
extracts (5 mg) were incubated with 0.2 ng of the indicated DNA
probe and 2 mg of poly(dI-dC) (Amersham Pharmacia Biotech)
in a binding buffer containing 20 mM Hepes, pH 7.9, 4 mM
MgCl2, 0.5 mM DTT, 0.1 mM EDTA, and 10% glycerol at
room temperature for 15 min. For competition experiments, 50-
fold excess of primers containing GBP-ISRE, IFN-g–stimulated
protein 15 (ISG15)-ISRE (23), or nuclear factor (NF)-kB bind-
ing site (21) were included in the binding reaction. For supershift
assays, a total of 2 ng of antibodies against specific members of the
IRF family of transcription factors was also included in the reac-
tion. DNA–protein complexes were resolved by electrophoresis
in a 5% polyacrylamide gel as described previously (25).
PGE2 Detection. For quantification of PGE2 release from
macrophages, 5 3 105 cells per well were seeded on a 24-well
plate. The next day, cells were incubated with 500 ml of medium
only or medium supplemented with IFN-g (100 U/ml), and the
presence of PGE2 in the supernatants was measured by ELISA 24 h
later (Cayman Chemical; no. 514010).
Results
IFN-g Activates Transcription of the Cox-2 Gene. IFN-g
is a major activator of macrophages, a cell type in which
Cox-2 has been reported to be highly upregulated upon
exposure to several proinflammatory signals. Initially, we
characterized the effect of IFN-g on Cox-2 gene expres-
sion. Peritoneal exudate macrophages were isolated from
C57BL/6 mice and treated in vitro with IFN-g for differ-
ent periods of time. RNA isolated from each treatment was
converted to cDNA and amplified by PCR for Cox-2,
Cox-1, and HPRT as control. Cox-2 transcripts were de-
tected within 1 h after incubation with IFN-g, peaked at 6 h,
Figure 1. IFN-g activation of Cox-2
gene expression. (A) Peritoneal macro-
phages from C57BL/6 mice were treated
for the indicated amounts of time with 10
U/ml of murine IFN-g. Total RNA was iso-
lated from duplicate wells and subjected to
RT-PCR reactions with specific primers
for Cox-1, Cox-2, and HPRT. (B) Dose
response analysis of Cox-2 gene expression
for IFN-g. (C) Western blot analysis of total
protein extracts from peritoneal macrophages
incubated for different periods of time with
100 U/ml of IFN-g were performed using
anti–Cox-1 and anti–Cox-2 antibodies. (D)
Dose response analysis of Cox-1 and Cox-2
protein expression after 12 h of treatment
with medium only (0) or IFN-g.2134 IRF-1 and IRF-2 Regulation of the Cox-2 Gene
and slowly decreased after 9 h (Fig. 1 A). In contrast to
Cox-2, IFN-g treatment resulted in a very modest decrease
in the steady-state levels of Cox-1 mRNA after 9 h, consis-
tent with previous observations (26). Equivalence of RNA
loading was verified by the consistency of HPRT mRNA
housekeeping signals. Moreover, previous studies from our
laboratory, also carried out with peritoneal exudate mac-
rophages, indicate that over this period of time, IFN-g fails
to induce either macrophage apoptosis or necrosis (27).
Treatment of macrophages with different doses of IFN-g
for 6 h showed a peak in mRNA with 10–100 U/ml (Fig.
1 B), although detectable levels of Cox-2 transcript were
observed after treatment with as little as 0.5 or 1 U/ml
IFN-g. To analyze the effect of IFN-g on Cox-2 protein
production, we performed Western blot analyses using
Cox-2–specific antibodies (Fig. 1, C and D). Cox-2 pro-
tein peaked after 12 h of IFN-g treatment, reaching a pla-
teau that persisted for .30 h. This induction was detect-
able with concentrations as low as 10 U/ml of IFN-g.
Taken together, these data indicate that steady-state Cox-2
mRNA expression and protein synthesis are upregulated by
IFN-g in mouse peritoneal macrophages.
IFN-g Synergizes with LPS and IL-1a to Induce Cox-2
mRNA and Protein Expression. LPS (28–32) and IL-1a
(33, 34) are two powerful inducers of Cox-2 expression in
several cell types. We sought to analyze if pretreatment of
macrophages with IFN-g would affect activation of Cox-2
by these two inducers. When we analyzed steady-state lev-
els of Cox-2 mRNA after 2 h of treatment with IL-1a or
LPS in the absence of IFN-g, clearly detectable amounts of
Cox-2 transcript were observed in LPS-treated macro-
phages, yet only a barely detectable signal was observed in
response to IL-1a (Fig. 2 A; compare lanes 1 and 7 for IL-
1a, and lanes 1 and 13 for LPS). Concurrent treatment of
cells with IFN-g and IL-1a (lane 8) or LPS (lane 14)
slightly augmented the signal seen in the absence of IFN-g.
Preincubation of macrophages with IFN-g for longer time
periods produced a significant enhancement of both IL-
1a– (lanes 9–12) and LPS-dependent (lanes 15–18) Cox-2
mRNA induction. This coactivation peaks after 6–8 h of
pretreatment with IFN-g, enhancing mRNA accumula-
tion z10-fold over levels detected after 2 h of treatment
with either inducer alone (compare lanes 7 and 12 for IL-
1a and lanes 13 and 18 for LPS).
Analysis of Cox-2 protein revealed similar results (Fig. 2 B).
Although IFN-g alone activated the expression of Cox-2
(lanes 3 and 4), it strikingly increased the levels of Cox-2
induced by IL-1a (compare lanes 5 and 6 with lanes 9 and
10) or LPS (compare lanes 7 and 8 with lanes 11 and 12)
alone. To investigate whether IFN-g and LPS or IL1-a co-
activate Cox-2 expression transcriptionally, transient trans-
fections using a luciferase reporter containing z2.1 kb of
the murine Cox-2 promoter (PGHS-2 medium) were per-
formed in RAW 264.7 macrophages (Fig. 2 C). IFN-g
alone increased the activity of this reporter almost twofold,
which is comparable to the activation obtained with a low
dose of LPS (1 ng/ml). However, when transfected cells
were preincubated with IFN-g for 6 h, activation by LPS
was substantially augmented. Similar treatments did not af-
fect luciferase activity in cells transfected with a minimal
Cox-2 promoter (Fig. 2C; PGHS-2 [243]). Although sim-
ilar experiments were conducted using IL-1a as the in-
Figure 2. IFN-g synergizes with IL-1a and LPS for Cox-2 expression.
(A) Peritoneal macrophages were either untreated (lanes 1, 7, and 13) or
pretreated with 10 U/ml of IFN-g (lanes 2–6, 8–12, and 14–13) for the
indicated periods of time (top) before the addition of media (lanes 1–6),
IL-1a (10 ng/ml, lanes 7–12), or LPS (0.1 ng/ml, lanes 13–18) for 2 h.
Time 0 of IFN-g priming represents the point at which IL-1a or LPS
was added to the cultures for 2 h. (B) Western blot analysis of priming ex-
periment for Cox-1 and Cox-2 proteins. Cells were primed with 10
U/ml of IFN-g for 12 h (1) and subsequently incubated with two con-
centrations of IL-1a (triangle; 1 and 10 ng/ml) or LPS (triangle; 0.1 and
0.5 ng/ml) for another 12 h. Results shown are representative of three in-
dependent experiments. (C) Transient transfection assay using the Cox-2
luciferase reporter (PGHS-2 medium) or a minimal Cox-2 promoter
(PGHS-2 [243]) in RAW 264.7 cells. After transfection, cells were left
untreated (media) or were pretreated with IFN-g (10 U/ml) for 6 h. The
media was replaced with IFN-g alone, LPS alone, or IFN-g plus LPS (1
ng/ml), and incubation continued for an additional 18 h. Results are the
means of six independent experiments 6 SD.2135 Blanco et al.
ducer, the effect on Cox-2 RNA and protein levels seen in
peritoneal macrophages could not be mimicked in lu-
ciferase reporter assay, which is likely to reflect the predom-
inant posttranscriptional regulation of Cox-2 expression by
IL-1a (34). However, IL-1a treatment did not affect the
IFN-g–dependent activation of the Cox-2 luciferase pro-
moter construct (data not shown). Together, these data in-
dicate that IFN-g enhances Cox-2 expression induced by
both IL-1a and LPS in mouse peritoneal macrophages, ren-
dering it more sensitive to induction by these activators.
IRFs Are Involved in the Regulation of Cox-2 Gene.
Members of the IRF family of transcription factors have
been demonstrated to play a major role in the regulation of
several inflammatory genes including iNOS (12, 35, 36)
and IL-12 p40 and IL-12 p35 (13, 37). IRF-1 is induced
early by IFN-g (38) through a STAT-1–dependent path-
way (39) and acts as a transcriptional activator, whereas
IRF-2 is expressed constitutively and is commonly de-
scribed as an antagonist of IRF-1–dependent activation (7,
8, 40). We took advantage of mice with targeted disrup-
tions in IRF-1 or IRF-2 genes for the analysis of the ex-
pression of Cox-2 after treatment with IFN-g alone or in
combination with LPS or IL-1a.
IFN-g was unable to activate Cox-2 mRNA expression
in IRF-12/2 macrophages (Fig. 3 A; IRF-12/2, lanes 7 and
10) when compared with the control IRF-11/1 macro-
phages. Moreover, synergy for steady-state Cox-2 mRNA
expression between IL-1a or LPS and either concentration
of IFN-g was abrogated in IRF-12/2 macrophages (com-
pare lanes 3 and 4 with lanes 8 and 11 for IL-1a, and lanes
5 and 6 with lanes 9 and 12 for LPS). Cox-2 protein ex-
pression was also analyzed in IRF-12/2 macrophages (Fig.
3 B). We found that after IFN-g treatment, these cells
were unable to produce any Cox-2 (Fig. 3 B; lanes 3 and
4). Moreover, IFN-g priming did not result in IL-1a– or
LPS-dependent synergy in Cox-2 protein expression (Fig.
3 B; compare lanes 5–8 with 9–12 from IRF-12/2 and
IRF-11/1), consistent with the steady-state mRNA data.
One additional point to be made is that Cox-2 mRNA was
upregulated in IRF-12/2 macrophages treated with IL-1a
only (lanes 3 and 4), although this was not observed at the
level of protein.
Figure 3. Regulation of the expression of Cox-2 in IRF-1– and IRF-2–deficient macrophages. (A) RT-PCR analysis of the expression of Cox-1,
Cox-2, and HPRT in IRF-1–deficient macrophages (IRF-12/2) compared with background-matched controls (IRF-11/1). Cells were treated with IL-
1a (lanes 3 and 4; 10 ng/ml), LPS (lanes 5 and 6; 1 ng/ml), and IFN-g (lanes 7 and 10; 10 and 100 U/ml, respectively) alone for 2 h or after pretreatment
with IFN-g for 6 h (lanes 7–12). (B) Western blot analysis of Cox-1 and Cox-2 protein expression in IRF-1–deficient macrophages after stimulation
with IFN-g (triangle; 10 and 100 U/ml), LPS (0.1 and 0.5 ng/ml), and IL-1a (1 and 10 ng/ml) alone or after priming for 12 h with 10 U/ml of IFN-g
(1). Results presented are representative of two independent experiments. (C) and (D) Similar to A and B, but using IRF-2–deficient macrophages (IRF-
22/2) or their background-matched controls (IRF-21/1). Results shown are representative of four independent experiments.2136 IRF-1 and IRF-2 Regulation of the Cox-2 Gene
In the case of IRF-22/2 macrophages (Fig. 3 C), higher
levels of expression of steady-state Cox-2 mRNA were ob-
served in the absence of inducers compared with control
macrophages (compare lanes 1 and 2 in IRF-22/2 versus
IRF-21/1), as well as in the IL-1a–dependent activation
(lanes 3 and 4). This increase in the basal level was also evi-
dent at the level of Cox-2 protein expression (Fig. 3 D), in
which IRF-2–deficient macrophages are more responsive
to these inducers (compare IRF-22/2 versus IRF-21/1 for
all treatments).
To analyze how the absence of IRF-1 or IRF-2 affects
final production of PGs, we measured PGE2, one of several
possible prostanoid products that is dependent on Cox-2
activity, in supernatants of IRF-12/2, IRF-22/2, and
C57BL/61/1 macrophages after stimulation with IFN-g
(Table I). No significant difference in PGE2 production by
these macrophages was observed, either basally or in the
first 12 h after treatment with IFN-g (data not shown).
However, after 24 h of IFN-g treatment, IRF-22/2 mac-
rophages showed the highest release of PGE2, followed by
C57BL/61/1, whereas IRF-12/2 macrophages showed no
PGE2 production, as expected. In fact, IRF-12/2 macro-
phages failed to exhibit increased PGE2 release in response to
IFN-g together with LPS (data not shown). Taken to-
gether, these data indicate that IRF-1 and IRF-2 are di-
rectly involved in the regulation of Cox-2 gene expression
and, ultimately, PGE2 production. Thus, IRF-1 acts as an
inducible transcriptional activator, as IRF-12/2 macrophages
are deficient in (a) IFN-g–dependent activation of the
Cox-2 gene, (b) IFN-g–dependent coactivation of IL-1a–
or LPS-dependent Cox-2 transcription, and (c) Cox-2 pro-
tein expression and release of PGE2. In contrast, IRF-2 is
involved in the repression of Cox-2 gene transcription.
This statement is supported by (a) the observed increase in
the basal and inducible transcription of Cox-2 gene, (b) the
increased levels of Cox-2 protein expression, and (c) the el-
evated levels of PGE2 after 24 h of activation of IRF-22/2
macrophages by IFN-g.
IRF-1 and IRF-2 Bind to the Cox-2 Promoter. Two
overlapping fragments (labeled “A” and “B” on Fig. 4 A),
similar in size and spanning z2.1 kb of the mouse Cox-2
promoter (sequence data available from EMBL/GenBank/
DDBJ under accession no. S82456; reference 20), were
synthesized and independently conjugated to magnetic
beads. The beads were then incubated with nuclear extracts
from the RAW 264.7 macrophage cell line pretreated with
IFN-g for 3 h. The proteins that bound to the immobilized
DNA fragments were analyzed by Western blot analysis us-
ing antibodies against IRF-1, IRF-2, or ICSBP (Fig. 4 B),
three members of the IRF family of transcription factors
that are expressed at high levels in these cells after IFN-g
Table I. PGE2 Production in C57BL/61/1, IRF-12/2, and 
IRF-22/2 Macrophages
PGE2 released
Macrophage type Medium IFN-g
(ng/ml)
C57BL/61/1 5.6 6 0.5 7.4 6 0.5
IRF-12/2 4.5 6 0.6 5.6 6 0.8
IRF-22/2 5.0 6 1.1 9.5 6 1.0
Macrophages were cultured for 24 h at a density of 5 3 105 cells in 24-
well plates in a final volume of 0.5 ml with medium only or medium
containing 100 U/ml of IFN-g. Results represent the mean 6 SD of
duplicate wells and were derived from a single experiment
representative of three independent experiments.
Figure 4. Two ISREs are located in the promoter region of the Cox-2
gene. (A) Schematic representation of the z2.1-kb promoter region of
the murine Cox-2 gene with the location of characterized binding sites
for several transcription factors, as well as two ISREs described in this pa-
per. A and B represent two overlapping DNA fragments used to locate
potential ISREs in the promoter. (B) Magnetic beads containing fragment
A or B, as well as beads containing the GBP-ISRE sequence (positive
control) or a mutant ISRE (Mut-ISRE; negative control), were incubated
with nuclear extracts of IFN-g–treated RAW 264.7 cells. Eluates were
analyzed by Western blot for the presence of IRF-1, IRF-2, or ICSBP.
The input lane represents 20% of the nuclear extract used for each lane
(50 mg). (C) Depiction of the sequence for the two ISREs found in the
mouse Cox-2 promoter (top) and their conservation with those found in
the human counterpart (bottom). In each case, numbers represent their
nucleotide position from the 11 transcription start site.2137 Blanco et al.
treatment (input lane represents 20% of total nuclear pro-
tein used for each assay). To control for the specificity of
this assay, beads containing DNA with three copies of the
ISRE found in the GBP promoter were used as a positive
control, whereas a mutated version of this ISRE was used
for controlling nonspecific binding (GBP-ISRE and Mut-
ISRE, respectively). Materials precipitated with beads con-
taining fragment A, which spans the region between
z22.1 and z20.9 kb of the promoter, showed detectable
levels of IRF-1 and IRF-2, but not ICSBP. The amount of
IRF-1 precipitated by this fragment was similar to the
amount precipitated by three in-tandem copies of the GBP-
ISRE beads, indicating similar binding capacities for IRF-1.
However, at least 10-fold less IRF-2 was precipitated by
fragment A, indicating a lesser affinity of this site for IRF-2.
No binding of these proteins was detected in beads contain-
ing fragment B, which encompasses the TATA box, initia-
tor sequence, and almost all sites involved in the activation
of the Cox-2 gene described to date (diagram in Fig. 4 A).
These data clearly demonstrate that the upstream portion
(22.1 to 20.9 kb) of the Cox-2 promoter is responsible for
the recruitment of IRF-1 and IRF-2.
Two ISRE Sites Found in Cox-2 Promoter. A computer
search for potential ISREs in the Cox-2 promoter region
using MatInspector 2.2 (41) resulted in two sequences that
partially match canonical ISREs (referred to as ISRE I for
the more upstream site and ISRE II for the downstream
site; Fig. 4 C). They are both located in the region of the
promoter that we previously defined as fragment A in our
bead assay (Fig. 4 A), indicating their potential role in the
binding of IRF family members to this fragment. Further-
more, these two sequences were highly conserved in the
human Cox-2 promoter (Fig. 4 C), especially in those nu-
cleotides that define the potential ISREs.
Figure 5. IRF-1 and IRF-2 bind to both Cox-2 ISREs. (A) EMSAs performed using probes containing the ISRE I and ISRE II from the murine
Cox-2 promoter and nuclear extracts from C57BL/6 macrophages incubated with IFN-g for different periods of time or doses, as indicated. “Free”
lanes represent the mobility of the probe without any extract added. Black arrowheads point to the IFN-g–inducible complex. Asterisks indicate the
constitutive complex. (B) DNA binding specificity experiments on ISRE I and ISRE II using for competition 50-fold excess of cold ISREs (GBP-
ISRE; lanes 4 and 10, and ISG15-ISRE; lanes 5 and 11) or a nonspecific competitor (NF-kB binding site; lanes 8 and 12). (C) Supershift experiments
on ISRE I and II using IRF-1– or IRF-2–specific antibodies as indicated. NS, nonspecific antiserum. (D) EMSA using control C57BL/61/1 or IRF-
12/2 and IRF-22/2 macrophages.2138 IRF-1 and IRF-2 Regulation of the Cox-2 Gene
Figure 6. Transcriptional regulation of
the Cox-2 promoter. (A) RAW 267.4 cells
were transiently transfected with the indi-
cated PGHS-2 luciferase reporters (left, 200 ng/each) along with control
empty vector to complete 200 ng (2) or increasing amounts of IRF-1
expression plasmid (1 5 100 ng and 11 5 200 ng). Results are ex-
pressed as fold induction relative to the activity of each reporter in the ab-
sence of IRF-1 plasmid, and represent the means from three independent
experiments 6 SD. Luciferase (Luc.) activity measured for PGHS-2 me-
dium in the absence of the IRF-1 construct and after normalization by
b-galactosidase activity was twice that obtained for PGHS-2 short, whereas
PGHS-2 (243) activity was ,1% of PGHS-2 medium. (B) RAW 267.4
cells were transfected with the indicated reporter plasmid (left) in the ab-
sence (2, control vector) or the presence of increasing amounts of IRF-1
(1 5 100 ng and 11 5 200 ng), and were completed to 200 ng with
control vector. After transfection, cells were treated with media or IFN-g
(10 U/ml) as indicated. Results are expressed as in A. Luc., luciferase;
ISRE II Mut, mutant ISRE II. (C) Cells were cotransfected with the
ISRE II (243) reporter along with either control vectors (500 ng), IRF-1
(125 ng), IRF-2 (375 ng), or IRF-1 expression plasmids in the presence
of increasing amounts of IRF-2 (125, 250, and 375 ng). Results represent
the means from three independent experiments 6 SD.2139 Blanco et al.
Both ISREs Found in the Cox-2 Promoter Form IFN-g–
inducible Complexes. Oligonucleotides containing both
ISRE sequences found in the Cox-2 promoter were end
labeled and used as probes for electrophoretic mobility shift
assay (EMSA). Incubation of these probes with nuclear ex-
tracts from untreated peritoneal macrophages resulted in a
distinct band (asterisk in Fig. 5 A; lanes 2 and 9) not present
in lanes containing free probes (lanes 1 and 8). Incubation
of cells with IFN-g for 1 or 3 h produced in both cases the
induction of a second band with slower mobility (black ar-
row in Fig. 5 A; lanes 3 and 4 for ISRE I, and lanes 10 and
11 for ISRE II). This band was more intense in ISRE II
than ISRE I, indicating a stronger binding activity of ISRE
II. Different doses of IFN-g were tested in the formation of
the inducible upper band (lanes 5–7 and 12–14). We deter-
mined that as little as 1 U/ml IFN-g for ISRE I or 0.1
U/ml for ISRE II was sufficient to stimulate the formation
of the upper complex. These data clearly indicate that both
ISREs found in the Cox-2 promoter are able to form con-
stitutive and IFN-g–inducible complexes with nuclear pro-
teins from murine macrophages. In both ISREs, the IFN-
g–inducible band was clearly competed with both GBP
and ISG15 cold ISRE probes, but not by a probe contain-
ing NF-kB binding site (Fig. 5 B).
IRF-1 and IRF-2 Form Complexes with Both Cox-2
ISREs. Our previous data with IRF-12/2 and IRF-22/2
macrophages (Fig. 3) indicated that IRF-1 and IRF-2 were
involved in the regulation of the expression of Cox-2 by
binding to its promoter (Fig. 4). Preincubation of EMSA
reactions with anti–IRF-1 antibody produced a clear su-
pershift of both ISRE I– and ISRE II–inducible bands (Fig.
5 C; lanes 4 and 10, asterisks), indicating the presence of
IRF-1 in these complexes. Antibodies against IRF-2 also
produced a supershift (lanes 5 and 11, arrows), although
displacement of the inducible band was less complete than
observed for anti–IRF-1 antibody.
To dissect further the composition of each complex, nu-
clear extracts from C57BL/61/1, IRF-12/2, and IRF-22/2
macrophages, untreated or treated with IFN-g, were used
for EMSA (Fig. 5 D). IRF-12/2 extracts were unable to
form the inducible upper complex seen in C57BL/61/1
extracts in the presence of IFN-g (compare lanes 3 and 5
for ISRE I and lanes 10 and 12 for ISRE II, arrows), dem-
onstrating that IRF-1 is part of this complex and is abso-
lutely necessary for its formation. IRF-2, on the other
hand, is not required for the formation of the inducible
bands, as these bands are present with IRF-22/2 extracts
and are enhanced in the presence of IFN-g (lanes 7 and 14,
arrows). However, a clear diminution of the constitutive
band formed by IRF-2 2/2 extracts and ISRE II in the
presence of IFN-g indicates that IRF-2 is part of this faster-
migrating complex (lane 14, asterisk). Taken together,
these data indicate that IRF-1 and IRF-2 bind through two
different ISREs located in the promoter of the Cox-2
gene. IRF-2 is part of the constitutive complex, whereas an
IRF-1–associated complex is induced by IFN-g.
Transcriptional Regulation of Cox-2 through ISREs. In
the transfection experiment shown in Fig. 2 C, we found
that IFN-g induced and coactivated LPS-dependent gene
transcription from a reporter driven by 2.1 kb of the Cox-2
promoter (PGHS-2 medium). To analyze the potential
transactivation characteristics of the ISREs located within
the Cox-2 promoter, RAW 264.7 cells were cotransfected
with a series of luciferase reporters (shown in Fig. 6 A, left),
along with increasing amounts of either an IRF-1 expres-
sion vector or a control plasmid. IRF-1 activated the
PGHS-2 medium reporter construct (Fig.6 A, top), which
contains both ISRE I and ISRE II, in a dose-dependent
manner, and reached a greater than threefold transactiva-
tion with the highest concentration of IRF-1 used (11;
Fig. 6 A, right). Removal of both ISREs, as is the case for
the PGHS-2 short construct or the Cox-2 basic promoter
(PGHS-2 [243]), completely abrogated IRF-1–dependent
transactivation, indicating the importance of these ISREs in
the whole promoter context. Although the PGHS-2 short
construct showed similar levels of activation compared with
PGHS-2 medium when cells were treated with IFN-g
alone, no coactivation with LPS and IFN-g was seen in
PGHS-2 short (data not shown), again indicating the im-
portance of the ISRE sequences.
To analyze further the transcriptional potential and spec-
ificity of each Cox-2 ISRE, reporter plasmids containing
three copies of each of these sites or mutated versions of
the same sequences were cloned in front of the basic Cox-2
promoter and tested (Fig. 6 B, left). Transcription could
be activated through both ISREs by IFN-g or by increas-
ing amounts of IRF-1, with levels comparable to those
seen for GBP-ISRE (Fig. 6 B, bottom), whereas the basic
promoter activity was not affected (Fig. 6 B, top). ISRE II
showed greater IFN-g– or IRF-1–dependent activation
than ISRE I, in agreement with the binding activity ob-
served for these ISREs in EMSA (compare ISRE I [243]
versus ISRE II [243] in Fig. 6 B). Mutation of two nucle-
otides located in the core TTTC of both ISRE sequences,
which destroyed the ISRE motif, completely abrogated
IFN-g– or IRF-1–dependent activation.
We showed previously that IRF-22/2 macrophages pos-
sess elevated Cox-2 mRNA and protein levels (Fig. 3, C and
D), suggesting a suppressive role of IRF-2 in this promoter.
Cotransfection of IRF-2 along with ISRE II (243) reporter
abrogated IFN-g–dependent activation of the luciferase ac-
tivity (Fig. 6 C, right; IRF-2). Moreover, it completely in-
hibited IRF-1–dependent activation when the highest dose
of IRF-2 was used, without affecting the LPS-dependent ac-
tivation of an unrelated AP1 reporter (Fig. 6 C, left). Taken
together, these data demonstrate that both ISREs located
upstream in the Cox-2 promoter are essential for IRF-1–
dependent activation. ISRE I and II are individually able to ac-
tivate transcription from a basic Cox-2 promoter in the pres-
ence of IRF-1, and mutations in these ISREs designed to
prevent IRF-1 binding were effective at abrogating transacti-
vation. Finally, we showed that IRF-2 works as a negative
regulator of Cox-2 promoter by inhibiting IFN-g– and
IRF-1–dependent activation by binding these ISREs.
IRF-12/2 Mice Are Unable to Sustain the LPS-induced Ex-
pression of the Cox-2 Gene in the Liver.  We showed in2140 IRF-1 and IRF-2 Regulation of the Cox-2 Gene
vitro that macrophages respond to LPS and IFN-g syner-
gistically to activate the expression of Cox-2. In vivo, intra-
peritoneal injection of mice with a sublethal dose of LPS
(25  mg/mouse) sharply increased expression of Cox-2
mRNA in liver within 1 h, with no detectable difference
between IRF-12/2 and IRF-11/1 responses (Fig. 7). Strik-
ingly, by 3 h after injection, IRF-12/2 mice exhibited a
progressive decline in the steady-state levels of Cox-2
mRNA, approaching almost undetectable levels at 12 h af-
ter injection, whereas levels of Cox-2 mRNA remained
fairly constant in the IRF-11/1 mice. This data clearly indi-
cates that the transcription factor IRF-1 plays a critical role
in vivo in the maintenance of Cox-2 expression over time.
Discussion
IFN-g is a well-characterized macrophage differentiation
signal. Macrophages pretreated with IFN-g achieve a
higher level of activation, e.g., IFN-g–primed macrophages
become more sensitive to other stimuli, such as bacterial
products and cytokines, as evidenced by the synergistic
induction of many inflammatory gene products, e.g., iNOS
(12, 35, 36) and IL-12 p40 (13, 37, 42, 43). In this paper,
we show that activation with IFN-g, as well as its priming
effect, can be extended to Cox-2, another gene with a cen-
tral role in inflammatory responses. Although IFN-g regu-
lation of Cox-2 has been described previously (26, 44, 45),
little is known of the molecular mechanisms that underlie
activation of this gene by IFN-g. For example, in bronchial
epithelial cells (44) and in normal human epidermal kerati-
nocytes (26), Cox-2 induction is controlled through auto-
crine loops via the epidermal growth factor receptor and its
ligands, such as TGF-a, resulting in a delayed activation.
However, in macrophages, Cox-2 mRNA induction was
detected as early as 1 h after IFN-g treatment, and the pro-
tein expression was detected after 6 h (Fig. 1), giving us the
first indication of a distinct inductive mechanism.
Strikingly, IRF-12/2 macrophages were unable to acti-
vate IFN-g–dependent transcription or synergize with LPS
or IL-1 to elicit Cox-2 (Fig. 3). The lack of Cox-2 expres-
sion was also reflected in the low levels of PGE2 produced
by these cells 24 h after treatment. Conversely, in the case
of IRF-22/2 macrophages, we showed an increase in the
basal level of Cox-2 transcription and Cox-2 protein, as
well as in the release of IFN-g–stimulated PGE2. We pre-
sented data that showed dysregulated PGE2 release in IRF-
12/2 and IRF-22/2 macrophages as one of the possible
outcomes of Cox-2 dysregulation. However, Cox-2 ex-
pression and PGE2 release are not always coordinated, and
other PGs or thromboxanes may be dysregulated as well.
Transfection studies have shown that IRF-1 can function as
an activator, inducing Cox-2 promoter constructs that
contain ISREs (6), whereas IRF-2 antagonizes the function
of IRF-1 by working as a repressor (7, 8). Both IRF-1 and
IRF-2 are normally expressed at very low levels in the cell
(7, 46). An increase in the intracellular concentration of
IRF-1 significantly alters the IRF-1/IRF-2 ratio because of
the fact that IRF-2 levels remain fairly stable throughout
the cell cycle. It has been shown that the modification of
this ratio can produce a dramatic change in the transcrip-
tion pattern of cells (46). Interestingly, increased levels of
Cox-2 expression have been associated with oncogenic and
inflammatory processes. For example, Cox-2 protein is un-
detectable in normal intestine (47), but its levels are ele-
vated in up to 85% of colorectal adenocarcinomas (48–50),
coincident with an increase in metastatic potential (51). It is
tempting to speculate that an altered IRF-1/IRF-2 ratio
may exist in those cells, which could anomalously activate
gene expression.
We found that Cox-2 gene regulation by IRF-1 and
IRF-2 is achieved through two unique ISREs located up-
stream of the Cox-2 promoter. Although the consensus
sequence for IRF-1/IRF-2 binding motif, (G/C)(A)AAA
(N)2–3AAA(G/C)(T/C) (6, 9), did not precisely match the
sequences of the ISREs described here, ISRE II partially
matched sequences previously cloned for their affinity for
IRF-1 and IRF-2 binding (52), but with a single base
change in the core sequence (GTA instead of GTG). ISRE I
and ISRE II were able to bind IRF-1 and IRF-2 in the
context of the whole promoter (Fig. 4), recruiting similar
amounts of IRF-1 compared with three copies of the
GBP-ISRE (53). Moreover, removal of these ISRE se-
quences from the promoter context completely abolished
IRF-1–dependent Cox-2 gene transcription (Fig. 6 A). We
found that PGHS-2 short, which does not contain the
novel ISREs described, is nonetheless able to direct tran-
scription induced by IFN-g alone, but unable to coactivate
transcription by IFN-g and LPS (data not shown). This
finding supports previous studies showing that IFN-g also
triggers secondary signals that enhance transcription
through downstream binding sites (non-ISRE; references
26, 36, 44, 54, 55). When analyzed separately, ISRE II was
more efficient at binding IRF-1 and IRF-2 complexes than
ISRE I, and although both ISREs were able to enhance
transcription of the basic Cox-2 promoter in an IFN-g and
IRF-1 dose–dependent manner, their different binding ac-
Figure 7. IRF-12/2 mice exhibit diminished
hepatic Cox-2 mRNA expression in response
to LPS in vivo. Control (IRF-11/1) and IRF-
12/2 mice were injected with 25 mg LPS intra-
peritoneally, and livers were collected at the in-
dicated times after injection. Total RNA was
prepared from individual mice (four per time
point) and was analyzed for Cox-2– and
HPRT-specific transcripts by RT-PCR.2141 Blanco et al.
tivities clearly correlated with distinct transactivation po-
tentials. Interestingly, homologous sites were also found in
the human Cox-2 promoter; they are located at a similar
distance from the transcription start site and follow a similar
orientation with respect to the entire promoter (Fig. 4 C).
IFN-g was also found to be a powerful coactivator of
IL-1a– and LPS-mediated induction of Cox-2 in mouse
peritoneal macrophages (Fig. 2). Pretreatment of macro-
phages with IFN-g clearly enhanced the activation induced
by IL-1a and LPS by .10-fold over that seen with either
of these inducers alone. Whereas LPS induction of Cox-2
is controlled in large measure at the level of transcription
(28, 32, 56), IL-1a regulates Cox-2 expression largely
through stabilization of Cox-2 mRNA (34), consistent
with our inability to detect IL-1a–mediated response in
transient transfection assays using the Cox-2 promoter. The
activation of Cox-2 by a combination of IFN-g and LPS
was described previously using the macrophage cell line
RAW 264.7 (45), although this effect was not seen in hu-
man peripheral blood monocytes (31). The synergy of
IFN-g with IL-1a for activation of Cox-2 protein expres-
sion and PGE2 release has also been controversial (57, 58).
Recently, Barrios-Rodiles and Chadee (58) described an
inhibitory effect of IFN-g priming on IL-1b–dependent
activation of Cox-2. These differences may possibly be at-
tributable to the different states of differentiation/activation
of the cells used in the different studies (monocytic or pro-
myelocytic cells treated with PMA compared with thiogly-
collate-elicited macrophages or the macrophage cells line
RAW 264.7). In addition to the two novel ISRE sites de-
scribed herein, other sites have been identified in the pro-
moter region of the Cox-2 gene, e.g., stimuli that activate
G proteins and protein kinases A and C can stimulate the
synthesis of Cox-2 by a process involving the cyclic AMP
response element (CRE) and E-box (Fig. 4 A; references
55, 59–61). Other inducers of Cox-2, like IL-1, TNF,
GM-CSF, and LPS, elicit their activity through the usage,
to varying extents, of NF-kB, NF–IL-6, and the CRE
binding sites also located within the Cox-2 promoter, and
are conserved among different species (32, 62–64). One
possible mechanism of IFN-g coactivation is the coopera-
tion between IRF-1, bound to both ISREs located up-
stream in the promoter, and the transcription factors that
bind to these downstream sites. Because IRF members
have been involved in the recruitment of histone acetylases
to the promoter environment (23), one additional but not
exclusive possibility is that IRF-1, after binding to the
ISREs, increases the concentration of these chromatin-
modifying activities in the promoter, making it more acces-
sible for the binding of other factors (65).
Moreover, IRF-1 is inducible by several cytokines (e.g.,
IL-1, TNF, IL-6 [52, 66, 67], IL-12 [68, 69]), and by LPS
(70), which have also been demonstrated to increase Cox-2
expression. This suggested the possibility that IRF-1 also
contributes to the regulation of Cox-2 gene expression by
these activators. Our findings using IRF-1– and IRF-2–
deficient macrophages confirm this relationship, as IL-1–
and LPS-dependent transcription and protein synthesis of
Cox-2 are clearly modified with respect to the response of
macrophages from normal control mice (Fig. 3; compare
stimulation with IL-1a and LPS individually).
With the data presented here, we have identified clear
parallels in the expression of iNOS and Cox-2 genes. Both
of these genes play essential roles in innate immune re-
sponses and inflammatory processes, being regulated at
transcriptional (36, 54, 71), posttranscriptional, and post-
translational levels (72, 73). iNOS gene expression is tran-
scriptionally induced by IFN-g and LPS in peritoneal mac-
rophages (74). Two ISREs in the promoter region of the
iNOS gene are involved in its IFN-g–dependent transcrip-
tional activation (12, 36). They are arranged in opposite
orientations, binding IRF-1 and activating transcription in
combination with p50/cRel and NF-kB sites in the pro-
moter (36, 54). IRF-12/2 macrophages are deficient in the
expression of iNOS and the production of NO after IFN-g
treatment (12, 13). Although iNOS regulation also shows a
dependency on ICSBP for its induction (75), we did not
detect binding of endogenous ICSBP to the Cox-2 pro-
moter under conditions employed. However, we cannot
rule out the possibility of a weak binding and a functional
role for this factor in the regulation of Cox-2 gene expres-
sion. Nevertheless, we found that IRF-2 is part of the con-
stitutive complex that binds to the Cox-2 ISREs. In the
absence of IRF-2, increases in basal and stimulated Cox-2
gene and protein expression were observed, with an associ-
ated increase in the PGE2 release upon IFN-g stimulation.
Overexpression of IRF-2 completely abolished IRF-1– as
well as IFN-g–dependent activation of the Cox-2 pro-
moter, indicating a silencing role for IRF-2. To date, the
negative regulation of Cox-2 gene expression by IRF-2,
and its potential for attenuating inflammatory responses, has
not been explored.
Focal cerebral ischemia has been associated with the up-
regulation of both iNOS and Cox-2 genes, which have
been implicated in the brain injury associated with stroke
(18, 76–78). In a mouse model of cerebral ischemia, it has
been shown that during the ischemic process, IRF-1
mRNA was upregulated in normal mice, whereas in IRF-
12/2 mice, there was attenuation of brain injury after
ischemia (79). Although the authors point out that a de-
crease in NO production may be one cause of this attenua-
tion, the data presented herein suggest that a decrease in
PG release secondary to attenuated Cox-2 production
may contribute to the decrease in the ischemic injury in
IRF-12/2 mice. Moreover, we found that IRF-12/2 mice
are unable to sustain steady-state mRNA production of
Cox-2 in the liver after intraperitoneal injection of LPS
(Fig. 7). We have confirmed that these mice are severely
deficient in the production of serum IFN-g after LPS
treatment when compared with IRF-11/1 controls (80;
data not shown). The peak of IFN-g production is at 8–12 h
after LPS injection (data not shown), which correlates
strongly with the sustained gene activation in IRF-11/1 mice.
Along the same lines, it has been reported that IRF-12/2
mice are less susceptible to LPS-induced mortality (80;
data not shown), which again suggests a role for Cox-22142 IRF-1 and IRF-2 Regulation of the Cox-2 Gene
and PG in the inflammatory response associated with septic
shock.
We have presented herein a detailed biological and
mechanistic analysis of the direct activation of Cox-2 gene
by IFN-g in freshly isolated macrophages, a major cellular
target for IFN-g and an important source of inflammatory
PGs. We have demonstrated for the first time that two
members of the IRF family of transcription factors, IRF-1
and IRF-2, regulate Cox-2 gene expression by their oppo-
site actions through two ISRE sites found in the promoter.
Moreover, we found that IRF-1 is necessary for the main-
tenance of hepatic Cox-2 gene expression by LPS in vivo.
Given the recent increase in interest in Cox-2 regulation in
the search for new antiinflammatory drugs, our data pro-
vide critical new information that may result in novel ther-
apeutic intervention strategies.
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